New tracers developed in positron emission tomography: A possible second breath in targeting tumour hypoxia?;Nouveaux traceurs en tomographie par émission de positons : un second souffle pour le ciblage de l'hypoxie tumorale ?

Medecine Nucleaire

Volumn 32, Issue 12, 2008, Pages 607-613

  Baillet, G ^a   Groheux, D ^a   Barre E ^a   Toubert, M E ^a   Dechaud, C ^a   Teyton, P ^a   Le Beau de Hemricourt, E ^b   Moretti, J L ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b Centre d'imagerie nucléaire Dunkerque   (France)

Author keywords

Cu ATSM; FAZA; Hypoxia; PET imaging

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; DIACETYL BIS[N(4) METHYLTHIOSEMICARBAZONE] CU II; FLUOROERYTHRONITROIMIDAZOLE F 18; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

ANGIOGENESIS; CELL LEVEL; DIAGNOSTIC VALUE; HUMAN; HYPOXEMIA; HYPOXIA; MEDICAL LITERATURE; POSITRON EMISSION TOMOGRAPHY; SHORT SURVEY;

EID: 57149129965     PISSN: 09281258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mednuc.2008.07.009     Document Type: Short Survey

References (53)

1. Vaupel P., and Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26 (2007) 225-239
2. Lewis J.S., and Welch M.J. PET imaging of hypoxia. Q J Nucl Med 45 (2001) 183-188
3. Lewis J.S., et al. Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone). J Nucl Med 43 (2002) 1557-1569
4. Myerson R.J., et al. Monitoring the effect of mild hyperthermia on tumour hypoxia by Cu-ATSM PET scanning. Int J Hyperthermia 22 (2006) 93-115
5. Beck R., et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med 48 (2007) 973-980
6. Chao K.S., et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49 (2001) 1171-1182
7. Grosu A.L., et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 69 (2007) 541-551
8. Rickhey M., and Bogner L. Application of the inverse Monte Carlo treatment planning system IKO for an inhomogeneous dose prescription in the sense of dose painting. Z Med Phys 16 (2006) 307-312
9. Semenza G.L. Life with Oxygen. Science 318 (2007) 62-64
10. Serganova I., et al. Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res 64 (2004) 6101-6108
11. Pouysségur J., Dayan F., and Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 (2006) 437-443
12. Kaushansky K. Lineage-Specific Hematopoietic Growth Factors. N Engl J Med 354 (2006) 2034-2045
13. Croce C.M. Oncogenes and Cancer. N Engl J Med 358 (2008) 502-511
14. Shaw R.J., and Cantley L.C. Ras, PI(3)k and mTOR signalling controls tumor cell growth. Nature 441 (2006) 424-430
15. Garber K. Energy deregulation: licensing tumors to grow. Science 312 (2006) 1158-1159
16. Mathieu D., and Mani R. A review of the clinical significance of tissue hypoxia measurements in lower extremity wound management. Int J Low Extrem Wound 6 (2007) 273-283
17. Nehmeh S.A., et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 70 (2008) 235-242
18. Vikram D.S., Zweier J.L., and Kuppusamy P. Methods for noninvasive imaging of tissue hypoxia. Antioxid Redox Signal 9 (2007) 1745-1756
19. Padhani A.R., et al. Imaging oxygenation of human tumours. Eur Radiol 17 (2007) 861-872
20. Padhani A. PET imaging of tumour hypoxia. Cancer Imaging 6 (2006) 117-121
21. Padhani A.R. Where are we with imaging oxygenation in human tumours?. Cancer Imaging 5 (2005) 128-130
22. Macapinlac H.A. Clinical applications of positron emission tomography/computed tomography treatment planning. Semin Nucl Med 38 (2008) 137-140
23. Van Baardwijk A., et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 43 (2007) 1392-1398
24. Newbold K., et al. Advanced imaging applied to radiotherapy planning in head and neck cancer: a clinical review. Br J Radiol 79 (2006) 554-561
25. Cher L.M., et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 47 (2006) 410-418
26. Cherk M.H., et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET. J Nucl Med 47 (2006) 1921-1926
27. Christian N., et al. Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model. Eur J Nucl Med Mol Imaging 34 (2007) 1348-1354
28. Rasey J.S., et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36 (1996) 417-428
29. Rasey J.S., et al. Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. Radiat Res 153 (2000) 84-92
30. Rajendran J.G., et al. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging 33 (2006) 44-53
31. Rajendran J.G., and Mankoff D.H. Beyond detection: novel applications for PET imaging to guide cancer therapy. J Nucl Med 48 (2007) 855-856
32. Rajendran J.G., et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 12 (2006) 5435-5441
33. Yang D.J., et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 194 (1995) 795-800
34. Dehdashti F., et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 30 (2003) 844-850
35. Dehdashti F., et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 55 (2003) 1233-1238
36. Dehdashti F., et al. Assessing tumor hypoxia in Cervical Cancer by PET with 60Cu-labeled Diacetyl-Bis (N4-methylthiosemicarbazone. J Nucl Med 49 (2008) 201-205
37. Grigsby P.W., et al. Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix. Mol Imaging Biol 9 (2007) 278-283
38. Laforest R., et al. Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur J Nucl Med Mol Imaging 32 (2005) 764-770
39. McQuade P., et al. Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents. Nucl Med Biol 32 (2005) 147-156
40. Matsumoto K., et al. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography. Int J Oncol 30 (2007) 873-881
41. O'Donoghue J.A., et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 61 (2005) 1493-1502
42. Yuan H., et al. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 47 (2006) 989-998
43. Tanaka T., et al. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. Nucl Med Biol 33 (2006) 743-750
44. Rust T.C., and Kadrmas D.J. Rapid dual-tracer PTSM + ATSM PET imaging of tumour blood flow and hypoxia: a simulation study. Phys Med Biol 51 (2006) 61-75
45. Wong T.Z., et al. PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator. AJR Am J Roentgenol 190 (2008) 427-432
46. Sorger D., et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 30 (2003) 317-326
47. Piert M., et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 46 (2005) 106-113
48. Reischl G., et al. Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation. Appl Radiat Isot 62 (2005) 897-901
49. Solomon B., et al. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Mol Cancer Ther 4 (2005) 1417-1422
50. Reischl G., et al. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results. J Pharm Pharm Sci 10 (2007) 203-211
51. Souvatzoglou M., et al. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging 34 (2007) 1566-1575
52. Seemann M.D., Beck R., and Ziegler S. In vivo tumor imaging in mice using a state-of-the-art clinical PET/CT in comparison with a small animal PET and a small animal CT. Technol Cancer Res Treat 5 (2006) 537-542
53. Riedl C.C., et al. Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic (18)F-MISO and (124)I-IAZG PET in the same study cohort. Eur J Nucl Med Mol Imaging 35 (2008) 39-46